Volume 92 Issue 15 | p. 6 | News of The Week
Issue Date: April 14, 2014

Daiichi Quits On Ranbaxy

Generics: India’s Sun Pharma will take on Ranbaxy and its quality woes
Department: Business
Keywords: M&A, generics, generic pharmaceuticals, India, Japan, FDA, GMP

A little more than five years after acquiring a majority stake in Ranbaxy Laboratories, Japan’s Daiichi Sankyo is throwing in the towel on the troubled Indian firm. Sun Pharmaceutical Industries, one of India’s largest manufacturers of generic drugs, will acquire Ranbaxy for about $4.0 billion.

Sun will pay for Ranbaxy with stock. When the deal is completed, Daiichi Sankyo will end up with a 9% stake in Sun . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society